IBIO, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
IBIO, INC. (IBIO) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$45.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-28
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$24.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$31.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $25.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was -$15.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2026 was -$45.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $159.00K.
- IBIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$150.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-28 | -$55.00K derived: sum of 2 quarters · filed 2026-08-28 | -$30.00K derived: sum of 3 quarters · filed 2026-08-28 | -$45.00K 10-K · filed 2026-08-28 |
| 2026-03-31 | -$31.00K 10-Q · filed 2026-05-12 | -$6.00K derived: sum of 2 quarters · filed 2026-05-12 | -$21.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $25.00K 10-Q · filed 2026-02-10 | $10.00K 10-Q · filed 2026-02-10 | ||
| 2025-09-30 | -$15.00K 10-Q/A · filed 2025-11-17 | |||
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-13 | $0.00 10-Q · filed 2024-05-13 | ||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-09 | |||
| 2023-06-30 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-24 | $113.00K derived: sum of 2 quarters · filed 2024-09-24 | $169.00K derived: sum of 3 quarters · filed 2024-09-24 | $159.00K 10-K/A · filed 2024-09-24 |
| 2023-03-31 | $113.00K 10-Q · filed 2024-05-13 | $169.00K derived: sum of 2 quarters · filed 2024-05-13 | $159.00K 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $56.00K 10-Q · filed 2024-05-13 | $46.00K 10-Q · filed 2024-02-09 | ||
| 2022-09-30 | -$10.00K 10-Q · filed 2024-05-13 | |||
| 2022-06-30 | -$150.00K 10-K · filed 2023-09-27 | |||
| 2022-03-31 | -$103.00K 10-Q · filed 2023-05-15 | -$130.00K derived: sum of 2 quarters · filed 2023-05-19 | -$131.00K derived: sum of 3 quarters · filed 2023-05-19 | |
| 2021-12-31 | -$27.00K 10-Q/A · filed 2023-05-19 | -$28.00K derived: sum of 2 quarters · filed 2023-05-19 | ||
| 2021-09-30 | -$1.00K 10-Q/A · filed 2023-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |